Species |
Human |
Protein Construction |
HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer [Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and HMTEVVRRC peptide] Accession # A0A140T913(HLA-A*02:01)&P61769(B2M)&HMTEVVRRC |
His |
Avi |
N-term |
|
C-term |
|
Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer, His & Avi, Human at 0.5μg/ml (100μl/well) on the plate can bind AntiB2M Antibody, mFc Tag. Test result was comparable to standard batch. |
Expression System |
HEK293 |
Theoretical Molecular Weight |
50.5 kDa |
Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 52-62 kDa based on Bis-Tris PAGE result. |
Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |

Immobilized HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer, His & Avi, Human, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 8.1 ng/ml determined by ELISA.

The purity of HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer, His & Avi, Humanr is greater than 95% as determined by SEC-HPLC.

HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Target Background |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. |
Synonyms |
MHC; HLA-A; P53; TP53; Antigen NY-CO-13; BCC7; FLJ92943; LFS1; TRP53 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.